Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson accrued rebates, returns and promotions (GTN) liability on balance sheet ($M) ($M)
Form 10-Q / 10-K Consolidated Balance Sheets
Latest, Q3 2026
18,936
Period ended Sep 30, 2026
Change on a year earlier
-11.3%
21,356 in Q3 2025
History
37 quarters
Since Q4 2016
Sources
35
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accrued rebates, returns and promotions (GTN) liability on balance sheet ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 18,936 | -11.3% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2026 | Jun 28, 2026 | 19,990 | -4.0% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2026 | Mar 29, 2026 | 18,399 | -2.0% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2025 | Dec 28, 2025 | 19,124 | +8.8% | Form 10-Q (filed 2026-10-21) ↗ |
| Q3 2025 | Sep 28, 2025 | 21,356 | +15.8% | Form 10-Q (filed 2025-10-22) ↗ |
| Q2 2025 | Jun 29, 2025 | 20,823 | +18.7% | Form 10-Q (filed 2025-07-24) ↗ |
| Q1 2025 | Mar 30, 2025 | 18,780 | +16.1% | Form 10-Q (filed 2025-04-23) ↗ |
| Q4 2024 | Dec 29, 2024 | 17,580 | +9.9% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2024 | Sep 29, 2024 | 18,439 | +16.6% | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2024 | Jun 30, 2024 | 17,539 | +11.9% | Form 10-Q (filed 2024-07-25) ↗ |
| Q1 2024 | Mar 31, 2024 | 16,182 | +9.5% | Form 10-Q (filed 2024-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 16,001 | +17.8% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2023 | Oct 1, 2023 | 15,808 | +12.7% | Form 10-Q (filed 2023-10-27) ↗ |
| Q2 2023 | Jul 2, 2023 | 15,672 | +16.5% | Form 10-Q (filed 2023-07-31) ↗ |
| Q1 2023 | Apr 2, 2023 | 14,784 | +14.0% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2022 | Jan 1, 2023 | 13,579 | +12.3% | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2022 | Oct 2, 2022 | 14,021 | +10.5% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2022 | Jul 3, 2022 | 13,447 | +8.0% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2022 | Apr 3, 2022 | 12,972 | +8.8% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2021 | Jan 2, 2022 | 12,095 | +5.1% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 12,683 | +2.1% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2021 | Jul 4, 2021 | 12,450 | +5.6% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 11,919 | +2.7% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2020 | Jan 3, 2021 | 11,513 | +5.8% | Form 10-K (filed 2022-02-17) ↗ |
| Q3 2020 | Sep 27, 2020 | 12,418 | +13.1% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2020 | Jun 28, 2020 | 11,790 | +13.0% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2020 | Mar 29, 2020 | 11,608 | +21.9% | Form 10-Q (filed 2020-04-29) ↗ |
| Q4 2019 | Dec 29, 2019 | 10,883 | +16.0% | Form 10-K (filed 2021-02-22) ↗ |
| Q3 2019 | Sep 29, 2019 | 10,977 | +26.4% | Form 10-Q (filed 2019-10-28) ↗ |
| Q2 2019 | Jun 30, 2019 | 10,433 | +19.7% | Form 10-Q (filed 2019-07-29) ↗ |
| Q1 2019 | Mar 31, 2019 | 9,523 | +19.7% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 9,380 | +30.1% | Form 10-Q (filed 2019-05-01) ↗ |
| Q3 2018 | Sep 30, 2018 | 8,684 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jul 1, 2018 | 8,717 | – | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2018 | Apr 1, 2018 | 7,956 | – | Form 10-Q (filed 2018-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 7,210 | +33.4% | Form 10-K (filed 2019-02-20) ↗ |
| Q4 2016 | Jan 1, 2017 | 5,403 | – | Form 10-K (filed 2018-02-21) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson Accrued rebates, returns and promotions (GTN) liability on balance sheet ($M) ($M), quarterly Q4 2016–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/gtn_rebates_liab
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.